IMTX: Immatics N.V.
Performance
IMTX -28.95%
Watchlist
Select an item
Summary
IMTX at a glance
IMTX returned -28.95% over the past year and -12.42% a year over five years. Its worst drop in that year was -47.94%, smaller than 25% of stocks on Redstone, and its Sharpe ratio of -0.37 beats 14% of stocks on Redstone. It pays no dividends.
Current Drawdown
-45.83%
Rolling Volatility
59.77%
Actions
Metrics
Risk Indicators
Alpha-35.59%
Beta1.45x
Sharpe-0.37
Sortino-0.52
Omega0.94
Calmar-0.60
Martin-1.02
Profile
About IMTX
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
- Sector
- Health Care
- Market cap
- $979M
- Listed
- Jul 2020
- Employees
- 407
- Website
- immatics.com
Comparisons